{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T23:21:41Z","timestamp":1769642501690,"version":"3.49.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-33731-y","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T04:25:56Z","timestamp":1766550356000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development and validation of a sustainable UHPLC method for quantification and impurity profiling of carfilzomib"],"prefix":"10.1038","volume":"16","author":[{"given":"Hitesh","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gayatri","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Payal","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"key":"33731_CR1","doi-asserted-by":"publisher","first-page":"607","DOI":"10.2217\/FON.11.42","volume":"7","author":"ML Khan","year":"2011","unstructured":"Khan, M. L. & Stewart, A. K. Carfilzomib: a novel second-generation proteasome inhibitor. Future Oncol. 7, 607\u2013612. https:\/\/doi.org\/10.2217\/FON.11.42 (2011).","journal-title":"Future Oncol."},{"key":"33731_CR2","doi-asserted-by":"publisher","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-13-0755","volume":"19","author":"TM Herndon","year":"2013","unstructured":"Herndon, T. M. et al. U.S. Food and drug administration approval: Carfilzomib for the treatment of multiple myeloma. Am. Assoc. Cancer. Res. 19, 4559\u20134563. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-0755 (2013).","journal-title":"Am. Assoc. Cancer. Res."},{"key":"33731_CR3","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.matpr.2019.04.174","volume":"14","author":"RR Gopireddy","year":"2019","unstructured":"Gopireddy, R. R. et al. DoE approach: A validated stability indicating RP-HPLC method development for the separation of diasteromeric analogs and process impurities of Carfilzomib. Mater. Today: Proc. 14, 514\u2013531. https:\/\/doi.org\/10.1016\/j.matpr.2019.04.174 (2019).","journal-title":"Mater. Today: Proc."},{"key":"33731_CR4","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jpba.2016.03.015","volume":"124","author":"V Sestak","year":"2016","unstructured":"Sestak, V., Roh, J., Klepalova, L. & Kovarikova, P. A UHPLC-UV-QTOF study on the stability of carfilzomib, a novel proteasome inhibitor. J. Pharm. Biomed. Anal. 124, 365\u2013373. https:\/\/doi.org\/10.1016\/j.jpba.2016.03.015 (2016).","journal-title":"J. Pharm. Biomed. Anal."},{"key":"33731_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s42452-019-0921-6","volume":"1","author":"V Bommuluri","year":"2019","unstructured":"Bommuluri, V. et al. Isolation, identification and characterization of new degradation products of Carfilzomib using high resolution mass spectrometry and nuclear magnetic resonance. SN Appl. Sci. 1, 1\u201314. https:\/\/doi.org\/10.1007\/s42452-019-0921-6 (2019).","journal-title":"SN Appl. Sci."},{"key":"33731_CR6","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.jpba.2017.08.048","volume":"146","author":"JS Min","year":"2017","unstructured":"Min, J. S. et al. Quantitative determination of Carfilzomib in mouse plasma by liquid chromatography\u2013tandem mass spectrometry and its application to a Pharmacokinetic study. J. Pharm. Biomed. Anal. 146, 341\u2013346. https:\/\/doi.org\/10.1016\/j.jpba.2017.08.048 (2017).","journal-title":"J. Pharm. Biomed. Anal."},{"key":"33731_CR7","doi-asserted-by":"publisher","first-page":"281","DOI":"10.31032\/ijbpas\/2022\/11.1.2026","volume":"11","author":"BJ Mali","year":"2022","unstructured":"Mali, B. J., Wagh, R. D. & Deore, B. L. Development and validation of bioanalytical method for Estimation of Carfilzomib in human plasma using RP-HPLC. Int. J. Biol. Pharm. Allied Sci. 11, 281\u2013289. https:\/\/doi.org\/10.31032\/ijbpas\/2022\/11.1.2026 (2022).","journal-title":"Int. J. Biol. Pharm. Allied Sci."},{"key":"33731_CR8","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3390\/separations10050318","volume":"10","author":"M Ibrahim","year":"2023","unstructured":"Ibrahim, M. et al. Application of quality by design approach in the optimization and development of the UPLC analytical method for determination of fusidic acid in pharmaceutical products. Separations 10, 318. https:\/\/doi.org\/10.3390\/separations10050318 (2023).","journal-title":"Separations"},{"key":"33731_CR9","doi-asserted-by":"publisher","unstructured":"Zuin, V. G., Segatto, M. L. & Ramin, L. Z. Green chemistry in analytical chemistry. In Green Chemistry and Chemical Engineering (eds. Sharma, S. & Mudhoo, A.) 613\u2013636.  https:\/\/doi.org\/10.1007\/978-1-4939-9060-3_1017 (2019).","DOI":"10.1007\/978-1-4939-9060-3_1017"},{"key":"33731_CR10","doi-asserted-by":"publisher","first-page":"10076","DOI":"10.1021\/acs.analchem.0c01887","volume":"92","author":"F Pena-Pereira","year":"2020","unstructured":"Pena-Pereira, F., Wojnowski, W. & Tobiszewski, M. AGREE\u2014Analytical greenness metric approach and software. Anal. Chem. 92, 10076\u201310082. https:\/\/doi.org\/10.1021\/acs.analchem.0c01887 (2020).","journal-title":"Anal. Chem."},{"key":"33731_CR11","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.talanta.2018.01.013","volume":"181","author":"J P\u0142otka-Wasylka","year":"2018","unstructured":"P\u0142otka-Wasylka, J. A new tool for the evaluation of the analytical procedure: green analytical procedure index. Talanta 181, 204\u2013209. https:\/\/doi.org\/10.1016\/j.talanta.2018.01.013 (2018).","journal-title":"Talanta"},{"key":"33731_CR12","unstructured":"U.S. Food and Drug Administration. Analytical procedures and methods validation for drugs and biologics & FDA. https:\/\/www.fda.gov\/files\/drugs\/published\/Analytical-Procedures-and-Methods-Validation-for-Drugs-and-Biologics.pdf (2015)."},{"key":"33731_CR13","unstructured":"International Council for Harmonisation. ICH Q2 (R2) Guideline: Validation of Analytical Procedures. ICH. https:\/\/database.ich.org\/sites\/default\/files\/ICH_Q2-R2_Document_Step2_Guideline_2022_0324.pdf  (2022)."},{"key":"33731_CR14","unstructured":"International Council for Harmonisation. ICH Q14 Guideline: Analytical Procedure Development & ICH. https:\/\/database.ich.org\/sites\/default\/files\/ICH_Q14_Document_Step2_Guideline_2022_0324.pdf (2022)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-33731-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-33731-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-33731-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T10:36:48Z","timestamp":1769596608000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-33731-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["33731"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-33731-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]},"assertion":[{"value":"23 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3788"}}